Mosaiques' proteomic analysis has established a leading position in clinical applications, particularly in diagnostics, therapy assessment, and drug development. This success is built on the use of reliable and reproducible clinical proteomic biomarkers, as well as a proprietary database.

• Clinical Relevance and Consistency: The value and clinical utility of Mosaiques' comprehensive protein analysis—which represents the "handprint" of an individual's proteome—have been demonstrated in over 100 clinical studies. A key factor in demonstrating this benefit is the method developed by Mosaiques, which provides consistently reproducible results and is continually monitored using appropriate standard samples (e.g., urine).

• Extensive Published Scientific Evidence: Mosaiques has set a high standard of transparency by publishing its scientific results in leading peer-reviewed journals.

• Comprehensive Identification of the Urine Proteome: The urine proteome is precisely mapped, identifying over 24,000 different proteins and peptides detectable in a single sample. This is made possible by a unique database containing over 85,000 data sets collected over 20 years. No other provider has a comparable database or such a detailed understanding of peptides and proteins in urine, including their distribution.

• Proven Validity of the Technology: The reliability of the technology has been demonstrated in over 100 studies and more than 400 scientific publications. This includes the reproducibility of sample preparation, the robustness of the analytical platform, and the consistency of data evaluation. This solid foundation allows for the seamless comparison of data from samples measured 20 years ago with current data. The exceptional longevity and robustness of the technology—recognized by a Letter of Support from the US-FDA, among others—ensure precise and reproducible analysis of individual proteomic data. It also enables the detection of changes in the proteome over time, in response to therapies, or due to lifestyle factors. This reliable analysis forms the foundation for identifying effective drugs that target specific proteins.

• Advanced Data Analysis and AI: Mosaiques identifies proteins and peptides in urine that exhibit significant changes in certain diseases and integrates these changes into a classification factor. This process is facilitated by AI and specialized algorithms that operate in a high-dimensional data space. These classification factors are typically based on hundreds of different proteins and peptides, with their individual distribution in each sample analyzed and combined using proprietary algorithms. To achieve this level of precision, a robust database and in-depth knowledge of disease-specific changes are essential—knowledge that Mosaiques can provide due to its extensive number of measurements and reliable technology.

More information can be found at our mosaiques' web page.